These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 16698684)

  • 1. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.
    Numbenjapon T; Serrano LM; Chang WC; Forman SJ; Jensen MC; Cooper LJ
    Exp Hematol; 2007 Jul; 35(7):1083-90. PubMed ID: 17588477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
    Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
    Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2.
    Yamaguchi Y; Ohta K; Shimizu K; Minami K; Noma K; Hihara J; Toge T
    Anticancer Res; 2001; 21(1B):669-77. PubMed ID: 11299824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
    Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
    Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
    Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
    Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
    Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J
    Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
    Bae J; Martinson JA; Klingemann HG
    Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
    Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J
    Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
    Marin V; Dander E; Biagi E; Introna M; Fazio G; Biondi A; D'Amico G
    Exp Hematol; 2006 Sep; 34(9):1219-29. PubMed ID: 16939815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
    Cheadle EJ; Hawkins RE; Batha H; O'Neill AL; Dovedi SJ; Gilham DE
    J Immunol; 2010 Feb; 184(4):1885-96. PubMed ID: 20089697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
    Tam YK; Martinson JA; Doligosa K; Klingemann HG
    Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.
    Jensen MC; Cooper LJ; Wu AM; Forman SJ; Raubitschek A
    Cytotherapy; 2003; 5(2):131-8. PubMed ID: 12745575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.
    Cheadle EJ; Gilham DE; Thistlethwaite FC; Radford JA; Hawkins RE
    Br J Haematol; 2005 May; 129(3):322-32. PubMed ID: 15842655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
    Jensen MC; Popplewell L; Cooper LJ; DiGiusto D; Kalos M; Ostberg JR; Forman SJ
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1245-56. PubMed ID: 20304086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.